Research
Hormonal
Slow-wave activity (SWA, 0.75-4.5 Hz) in non-REM sleep is modulated by both the circadian pacemaker and the homeostatic sleep process, with the circadian modulation peaking around the minimum of the core body temperature rhythm.
Deep sleep (SWA) is highest when you sleep during your biological night (temperature minimum). Additionally, SWA increases with the duration of prior wakefulness. To maximize deep sleep, ensure you are sleep-deprived enough (homeostatic pressure) and sleeping during your circadian night.
StrongSupportsHIGH confidence
Slow-wave activity... exhibited a circadian modulation... The crest of the circadian rhythm of SWA coincident with the minimum of the core body temperature rhythm... Slow-wave activity increased in the course of the homeostatic process... The interaction between circadian and sleep dependent components... was analyzed.
Why this rating
Robust experimental design.
Source
Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans
Derk‐Jan Dijk et al. · Journal of Neuroscience · 1995
DOI 10.1523/jneurosci.15-05-03526.1995
rct · n=8Cited 1,346×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The endogenous circadian pacemaker significantly modulates sleep propensity, with sleep latency being shortest (highest propensity) when sleep coincides with the minimum of the core body temperature rhythm, and longest (lowest propensity) when it coincides with the maximum.Strong
- Total sleep time and sleep efficiency are significantly modulated by the circadian phase, being highest when the scheduled sleep episode coincides with the falling and plateau phases of the core body temperature rhythm, and lowest when it coincides with the rising phase.Strong
- The circadian pacemaker significantly modulates the amount of REM sleep, with maximum REM sleep occurring shortly after the minimum of the core body temperature rhythm, and minimum REM sleep occurring during the plateau phase.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →